AI reignites biotech bets but human clinical validation remains key hurdle

Kinea Investimentos study assesses AI's impact on pharma, noting renewed investor interest in biotech but emphasizing that human clinical validation remains the decisive test. The report suggests AI-driven drug discovery optimism is not yet confirmed by late-stage trial outcomes.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works